新型佐剂sVSSP作为HPV16治疗性疫苗组分对 antitumor 应答的影响
宫颈癌是全球公共卫生问题,HPV16约占全球病例的50%。研究开发了融合蛋白CIGB550-E7(含细胞穿透肽与E7突变体),先前证明其联合VSSP佐剂可诱导抗肿瘤应答。本研究在小鼠中比较CIGB550-E7联合新型佐剂sVSSP(不含动物源性成分)的免疫效果,获得类似的抗肿瘤应答,并诱导细胞介导免疫应答。
要点
- CIGB550-E7联合sVSSP在小鼠中诱导与VSSP类似的抗肿瘤应答
- sVSSP佐剂不含动物源性成分
- 该疫苗制剂诱导细胞介导的免疫应答
核心结论
- CIGB550-E7联合新型佐剂sVSSP在小鼠中诱导与VSSP类似的抗肿瘤应答,并诱导细胞介导免疫应答,支持后续临床试验。
研究设计与样本
- 小鼠免疫实验研究,比较CIGB550-E7联合sVSSP与联合VSSP的抗肿瘤应答。
主要发现
- CIGB550-E7联合sVSSP免疫小鼠获得与联合VSSP类似的抗肿瘤应答。
- 该疫苗制剂免疫诱导细胞介导的免疫应答。
关键数值与推荐
- HPV16约占全球宫颈癌病例的50%。
临床怎么用
- 为CIGB550-E7+sVSSP候选疫苗的未来临床试验提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cervical cancer is a global public health problem and human papillomavirus (HPV) 16 accounts for approximately 50% of cases worldwide. Although there are several types of HPV therapeutic vaccines in clinical research, there are currently not approved for use in humans. We developed the fusion protein LALF32-51-E7 (hereafter denominated CIGB550-E7) defined by a cell-penetrating peptide linked to an E7 mutein for the treatment of HPV16-associated tumors. We have demonstrated previously the benefit on antitumor response induced by the immunization with CIGB550-E7 admixed with very small size proteoliposomes (VSSP) adjuvant compared with the adjuvant-free immunization. In this study, we obtained a similar antitumor response in mice immunized with CIGB550-E7 admixed with the new adjuvant sVSSP that does not contain any animal-derived product. Also, the immunization with the above mentioned vaccine preparation induced a cell-mediated immune response. Our results are encouraging for the future clinical trials with the vaccine candidate CIGB550-E7+sVSSP.
引用
- Granadillo M, Batte A, Alfonso AB, et al. Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate. Vaccine. 2019. PMID: 31155419. doi:10.1016/j.vaccine.2019.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。